The release of positive Phase III results for Sanofi-Aventis' next-generation chemotherapy agent cabazitaxel in hormone resistant prostate cancer could put a damper on recruitment for clinical trials of other late-stage drug trials in the same indication. Sanofi presented the first evidence of a survival benefit in HRPC (also called castration-resistant prostate cancer) in patients who failed chemotherapy in the Phase III TROPIC study on March 5 at the American Society of Clinical Oncology's 2010...